Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.66 |
| ▸ | TK2 | O00142 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL933041 | 1.00 | TK1 (0.66) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| Phosphoric Acid SCHEMBL8600183 | 0.96 | TK1 (0.61) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL21585108 | 0.94 | TK1 (0.63) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL3931463 | 0.94 | TK1 (0.63) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL3931456 | 0.94 | TK1 (0.63) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL7166566 | 0.93 | TK1 (0.62) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL7166563 | 0.93 | TK1 (0.62) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL4263815 | 0.92 | TK1 (0.61) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL7172039 | 0.92 | TK1 (0.61) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL7170550 | 0.92 | TK1 (0.61) | TK1TK2LMNASMN1; SMN2ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 316 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3149167-B1 | APTAMER TARGETING MAGE-A3 PEPTIDE AND USES THEREOF | ACADEMIA SINICA (TW) | 2019-09-04 | — | — | EP | claimed |
| US-9976146-B2 | Aptamer targeting MAGE-A3 peptide and uses thereof | IANALYZER INCORPORATION (TW) | 2018-05-22 | — | — | US | claimed |
| US-20170183660-A1 | APTAMER TARGETING MAGE-A3 PEPTIDE AND USES THEREOF | ACADEMIA SINICA (TW) | 2017-06-29 | — | — | US | claimed |
| EP-3149167-A1 | APTAMER TARGETING MAGE-A3 PEPTIDE AND USES THEREOF | Academia Sinica (TW) | 2017-04-05 | — | — | EP | claimed |
| WO-2015184224-A1 | APTAMER TARGETING MAGE-A3 PEPTIDE AND USES THEREOF | ACADEMIA SINICA (TW) | 2015-12-03 | — | — | WO | claimed |
| US-20260072019-A1 | METHOD OF DETERMINING THE PRESENCE OR ABSENCE OF A TARGET ANALYTE COMPRISING USING A REPORTER POLYNUCLEOTIDE AND A TRANSMEMBRANE PORE | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-03-12 | — | — | US | disclosed |
| US-12553085-B2 | Sequencing kit | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-02-17 | — | — | US | disclosed |
| US-20260028379-A1 | MUTANT PORE | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-01-29 | — | — | US | disclosed |
| US-12509721-B2 | Methods and systems for characterizing analytes using nanopores | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2025-12-30 | — | — | US | disclosed |
| EP-4665753-A1 | ARMOURED REGULATORY T CELL | King's College London (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-20250361502-A1 | Promoters And Compositions | UNIV OXFORD INNOVATION LTD (GB) | 2025-11-27 | — | — | US | disclosed |
| EP-3802877-B1 | METHOD | OXFORD NANOPORE TECH PLC (GB) | 2025-11-05 | — | — | EP | disclosed |
| US-5763208-A | Oligonucleotides and their analogs capable of passive cell membrane permeation | GILEAD SCIENCES, INC. (US) | 1998-06-09 | — | — | US | disclosed |
| US-5756291-A | IDENTIFYING OLIGOMER SEQUENCES; QUALITATIVE ANALYSIS; ANALYSIS OF THROMBIN BY COMPLEXING | GILEAD SCIENCES, INC. (US) | 1998-05-26 | — | — | US | disclosed |
| WO-1998016661-A2 | MORPHATIDES: NOVEL SHAPE AND STRUCTURE LIBRARIES | MORPHAGEN (US) | 1998-04-23 | — | — | WO | disclosed |
| WO-1998004575-A2 | LIPOPHILIC OLIGONUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1998-02-05 | — | — | WO | disclosed |
| US-5633360-A | CONTAINS AT LEAST TWO NUCLEOSIDE RESIDUES AND INTERNUCLEOTIDE LINKAGES | GILEAD SCIENCES, INC. (US) | 1997-05-27 | — | — | US | disclosed |
| EP-0572529-A1 | APTAMER SPECIFIC FOR BIOMOLECULES AND METHOD OF MAKING | GILEAD SCIENCES, INC. (US) | 1993-12-08 | — | — | EP | disclosed |
| WO-1992014842-A1 | APTAMERS SPECIFIC FOR THROMBIN AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 1992-09-03 | — | — | WO | disclosed |
| WO-1992014843-A1 | APTAMER SPECIFIC FOR BIOMOLECULES AND METHOD OF MAKING | GILEAD SCIENCES, INC. (US) | 1992-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260072019-A1 | METHOD OF DETERMINING THE PRESENCE OR ABSENCE OF A TARGET ANALYTE COMPRISING USING A REPORTER POLYNUCLEOTIDE AND A TRANSMEMBRANE PORE | NUP210, EPCAM, PHAX | TK1 1669/4885TK2 1257/4885LMNA 489/4885 |
| US-12509721-B2 | Methods and systems for characterizing analytes using nanopores | DNA2, MTREX, DDX21 | TK1 515/4885TK2 925/4885LMNA 134/4885 |
| US-12553085-B2 | Sequencing kit | PHAX, TIA1, POLM | TK1 653/4885TK2 702/4885LMNA 293/4885 |
| US-20260028379-A1 | MUTANT PORE | PTMS, NUP50, NUP205 | TK1 3314/4885TK2 2804/4885LMNA 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.